Compositions and methods for inducing gene expression

Details Compositions and methods for inducing gene expression Compositions and methods for inducing gene expression

2006-05-30

2006-05-30

Guzo, David (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100, C435S455000, C536S023400

Reexamination Certificate

active

07053062

ABSTRACT:
The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

REFERENCES:
patent: 5612318 (1997-03-01), Weichselbaum et al.
patent: 5674730 (1997-10-01), Baim
patent: 5707618 (1998-01-01), Armentano
patent: 5834306 (1998-11-01), Webster
patent: 6087166 (2000-07-01), Baron et al.
patent: 6121246 (2000-09-01), Isner
patent: 6124131 (2000-09-01), Semenza
patent: 6133027 (2000-10-01), Yee et al.
patent: WO 91/19784 (1991-12-01), None
patent: WO 96/26742 (1996-09-01), None
patent: WO 96/39426 (1996-12-01), None
patent: WO 98/31701 (1998-07-01), None
patent: WO 98/56936 (1998-12-01), None
Anderson et al, Human gene therapy, Apr. 30, 1998,Nature, vol. 392, pp. 25-30.
Bacon et al.,Biochemical and Biophysical Research Communications249: 811-816 (1988), “Regulation of the Drosophila bHLH-PAS Protein Sima by Hypoxia: Functional Evidence for Homology with Mammalian HIF-A Alpha”.
Banai et al.,Cardiovascular Res. 28: 1176-1179 (1994).
Benjamin et al.,Proc. Natl. Acad. Sci. USA87: 6263-6267 (1990).
Blanchard et al.,Molecular and Cellular Biology12: 5373-5385 (1992).
Blau et al.,Molecular and Cellular Biology16: 2044-2055 (1996).
Bunn et al.,Physiological Rev.76: 839-885 (1996).
Chiu et al., Optimizing energy potentials of success in protein tertiary structure prediction, May 1998, Folding & Design, vol. 3, pp. 223-228.
Cress et al.,Science251: 87-90 (1991).
Croston et al.,Genes&Development6: 2270-2281 (1992).
Dachs et al.,Nature Medicine3: 515-520 (1997).
Dejgaard et al.,Journal of Molecular Biology236: 33-48 (1990).
Ema et al.,Proc. Natl. Acad. Sci., USA94: 4273-4278 (1997).
Feldman et al.,Cardiovascular Res. 32: 194-207 (1996).
Finkel et al.,FASEB J. 9: 843-851 (1995).
Fishman,Trends Cardiovasc Med. 5: 211-217 (1995), “Conditional Transgenics”.
Fishman,Circ. Res., 82: 837-844 (1988), “Timing Is Everything in Life—Conditional Transgene Expression in the Cardiovascular System”.
Forsythe et al.,Molecular and Cellular Biology16: 4604-4613 (1996).
Gleadle and Ratcliffe.,Molecular Medicine Today, 122-129 (Mar. 1988), “Hypoxia and the Regulation of Gene Expression”.
Gu et al.,Gene Expression 7: 205-213 (1998).
Guillemin et al.,Cell 89: 9-12 (1997).
Gupta et al.,Nucleic Acids Research24: 2324-2330 (1996).
Hashimoto et al.,Am. J. Physiol. 267 (5 Part 1): H1948-H1954 (1994).
Henderson et al.,The Journal of Biological Chemistry264: 18142-18148 (1989), “Structure, Organization, and Expression of the Rat Cardiac Myosin Light Chain-2 Gene”.
Huang et al.,The Journal of Biological Chemistry271: 32253-32259 (1996).
Huang et al.,Proc. Natl. Acad. Sci. USA95: 7987-7992 (1988), “Regulation of Hypoxia-Inducible Factor 1 Alpha is Mediated by an O2-Dependent Degradation Domain Via the Ubiquitin-Proteasome Pathway”.
Jiang et al.,The Journal of Biological Chemistry271: 17771-17778 (1996).
Jiang et al.,The Journal of Biological Chemistry272: 19253-19260 (1997).
Kadonaga et al.,Cell51: 1079-1090 (1987), “Isolation of cDNA Encoding Transcription Factor Sp1 and Functional Analysis of the DNA Binding Domain.”
Karck et al.,Ann. Thorac. Surg. 59: 699-706 (1995).
Lee et al.,Nature325: 368-372 (1987), “Activation of Transcription by Two Factors that Bind Promoter and Enhancer Sequences of the Human Metallothionein Gene and SV40”.
Levy et al.,The Journal of Biological Chemistry270: 13333-13340 (1995).
Li et al.,The Journal of Biological Chemistry271: 21262-21267 (1996).
Li et al.,Ann Thorac Surg.62: 654-661 (1996), “Cardiomyocyte Transplantation Improves Heart Function”.
Maltepe et al.,Nature386: 403-407 (1997).
Mastrangelo et al., Gene Therapy for Human Cancer: An Essay for Clinicians, Feb. 1996, Seminars in Oncology, vol. 23, No. 1, pp. 4-21.
Meng et al., Tumor Supperssor Genes as Targets for Cancer Gene Therapy, 1999, Gene Therapy of Cancer, Chapter 1, pp. 3-20.
Mermod et al.,Cell58: 741-753 (1989), “The Proline-Rich Transcriptional Activator of CTF/NF-I is Distinct from the Replication and DNA Binding Domain”.
Neuman et al.,Gene173: 163-169 (1996), “Structure and Partical Genomic Sequence of the Human E2F1 Gene”.
Ngo et al., Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox, 1994, Birkhauaer Boston, pp. 491-495.
Norris et al.,The Journal of Biological Chemistry270: 23774-23779 (1995).
Pfeifer et al.,Cell56: 291-301 (1989), “Functional Dissection and Sequence of Yeast HAP1 Activator”.
Pinkham et al.,Molecular and Cellular Biology7: 578-585 (1987), “Sequence and Nuclear Localization of theSaccharomyces cerevisiaeHAP2 Protein, a Transcriptional Activator”.
Pollack and Gilman,Proc. Natl. Acad. Sci USA94: 13388-13389 (1997), “Transcriptional Activation: Is it Rocket Science?”.
Ptashne,Nature386: 569-577 (1997).
Ptashne,Nature Medicine3: 1069-1072 (1997).
Ptashne,Nature335: 683-689 (1988).
Pugh et al.,The Journal of Biological Chemistry272: 11205-11214 (1997).
Rabindran et al.,Proc. Natl. Acad. Sci. USA88: 6906-6910 (1991), “Molecular Cloning and Expression of a Human Heatshock Factor, HSF1”.
Regier et al.,Proc. Natl. Acad. Sci. USA90: 883-887 (1993).
Rinsch et al.,Human Gene Therapy8: 1881-1889 (1997).
Ruoquain-Shen et al.,Molecular and Cellular Biology11: 1676-1685 (1991), “Tissue-Specific Transcription of the Cardiac Myosin Light-Chain 2 Gene is Regulated by an Upstream Repressor Element”.
Schmitz and Baeuerle,The EMBO Journal10: 3805-3817 (1991), “The p65 subunit is Responsible for the Strong Transcription Activating Potential of NF-kappaB”.
Schmitz et al.,The Journal of Biological Chemistry269: 25613-25620 (1994), “Structural and Functional Analysis of the NF-kappaB p65 Terminus”.
Schmitz et al.,The Journal of Biological Chemistry270: 15576-15584 (1985), “Transactivation Domain 2 (TA2) of p65 NF-kappaB”.
Semenza et al.,The Journal of Biological Chemistry269: 23757-23763 (1994).
Semenza et al.,Kidney International51: 553-555 (1997).
Sengstag and Hinnen,Nucleic Acids Research15: 233-246 (1987), “The sequence of theSaccharomyces cerevisiaeGene PHO2 Codes for a Regulatory Protein with Unusual Aminoacid Composition”.
Shyu et al.,Circulation98: Abstract 342 (1998).
Simmen et al.,Journal of Virology71: 3886-3894 (1997).
Subramaniam et al.,The Journal of Biological Chemistry266: 24613-24620 (1991), “Tissue-specific Regulation of the Alpha-Myosin Heavy Chain Gene Promoter in Transgenic Mice*”.
Suzuki et al.,Molecular and Cellular Biology8: 4991-4999 (1988), “GAL11 Protein, an Auxilliary Transcription Activator for Genes Encoding Galactose-Metabolizing Enzymes inSaccharomyces cerevisiae”.
Tait et al., Ovarian Cancer BRCA1 Gene Therapy: Phase I and II Trial Differences in Immune Response and Vector Stability, Jul. 14, 1999, Clinical Cancer Research, vol. 5, pp. 1708-1714.
Tian et al.,Genes&Development11: 72-82 (1996).
Triezengerg,Genetics and Development5: 190-196 (1995), “Structure and Function of Transcriptional Activation Domains”.
Verma et al., Gene therapy-promises, problems, and propects, Sep. 18, 1997, Nature, vol. 389, pp. 239-242.
Vincent et al.,Anglogenesis and Vascular Remodeling(1998).
Wang et al.,The Journal of Biological Chemistry270: 1230-1237 (1995).
Wang et al.,Proc. Natl. Acad. Sci. USA92:

Affiliated with

Also associated with

Rating

Compositions and methods for inducing gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for inducing gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inducing gene expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3622020